Johnson Yiu Nam Lau - 22 Nov 2021 Form 4 Insider Report for Athenex, Inc.

Role
CEO and Chairman of the Board, Director
Signature
/s/Steven Adams, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Nov 2021
Net transactions value
+$5,520
Form type
4
Filing time
22 Nov 2021, 15:13:32 UTC
Previous filing
18 Nov 2021
Next filing
28 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Purchase $5,520 +3,000 +0.09% $1.84* 3,274,959 22 Nov 2021 Direct
holding ATNXQ Common Stock 678,880 22 Nov 2021 By Avalon Biomedical (Management) Limited F1, F2
holding ATNXQ Common Stock 164,925 22 Nov 2021 By Spouse F2
holding ATNXQ Common Stock 107,181 22 Nov 2021 By Avalon Polytom (HK) Limited F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATNXQ Stock Option (Right to Buy) 150,000 22 Nov 2021 Common Stock 150,000 $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 1,200,000 22 Nov 2021 Common Stock 1,200,000 $4.55 Direct
holding ATNXQ Stock Option (Right to Buy) 1,400,000 22 Nov 2021 Common Stock 1,400,000 $7.50 Direct
holding ATNXQ Stock Option (Right to Buy) 1 22 Nov 2021 Common Stock 1 $11.00 Direct
holding ATNXQ Stock Option (Right to Buy) 54,904 22 Nov 2021 Common Stock 54,904 $9.00 By Avalon Biomedical (Management) Limited F1, F2
holding ATNXQ Stock Option (Right to Buy) 250,000 22 Nov 2021 Common Stock 250,000 $17.30 Direct F4
holding ATNXQ Stock Option (Right to Buy) 250,000 22 Nov 2021 Common Stock 250,000 $13.17 Direct F5
holding ATNXQ Stock Option (Right to Buy) 55,045 22 Nov 2021 Common Stock 55,045 $7.32 Direct F6
holding ATNXQ Stock Option (Right to Buy) 300,000 22 Nov 2021 Common Stock 300,000 $12.45 Direct F7
holding ATNXQ Stock Option (Right to Buy) 150,000 22 Nov 2021 Common Stock 150,000 $3.80 Direct F8
holding ATNXQ Restricted Stock Units 150,000 22 Nov 2021 Common Stock 150,000 Direct F9, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Avalon Biomedical (Management) Limited ("Avalon Biomedical") is an indirect wholly-owned subsidiary of Avalon Global Holdings Limited ("Avalon Global"). Dr. Johnson Lau ("Dr. Lau") owns all of the outstanding interests in Creative Decade Global Limited, which owns 34.63% of the outstanding interests in Avalon Global, and Dr. Lau serves on the board of directors of Avalon Global and has shared voting and dispositive power with respect to the shares held by Avalon Biomedical.
F2 Dr. Lau disclaims beneficial ownership of the reported securities except to the extent, if any, of its or his pecuniary interest therein, and this report shall not be deemed an admission that Dr. Lau is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3 These shares were acquired pursuant to the terms of a License Agreement dated as of June 29, 2018 by and between Athenex Therapeutics Limited, a wholly-owned subsidiary of Athenex, Inc. ("Athenex") and Avalon Polytom (HK) Limited, a majority-owned affiliate of Avalon Global. The number of shares was determined by dividing $2.0 million by the closing price of Athenex common stock on June 29, 2018.
F4 This option vests in four equal annual installments beginning on March 27, 2019.
F5 This option vests in four equal annual installments beginning on February 28, 2020.
F6 This option was issued to the reporting person pursuant to the 2017 Omnibus Incentive Plan in lieu of $363,846.14 of base salary.
F7 This option vests in four equal annual installments beginning on June 5, 2021.
F8 This option vests in four equal annual installments beginning on August 3, 2022.
F9 Each restricted stock unit represents a contingent right to receive one share of stock.
F10 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.